Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
February 22 2021 - 4:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that it will report its full year 2020
financial results on Thursday, February 25th, 2021.
Altimmune management will host a conference call
for investors beginning at 8:30 am ET on Thursday, February 25th,
2021 to discuss financial results and provide a business
update.
Conference Call
Information:
| Date: |
Thursday, February 25, 2021 |
| Time: |
8:30 am Eastern Time |
| Domestic Dial-in: |
877-423-9813 |
| International Dial-in: |
201-689-8573 |
| Conference ID: |
13716171 |
| Webcast: |
http://public.viavid.com/index.php?id=143423 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical
company focused on developing intranasal vaccines, immune
modulating therapies and treatments for liver disease. Our diverse
pipeline includes proprietary intranasal vaccines for COVID-19
(AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an
intranasal immune modulating therapeutic for COVID-19 (T-COVID™);
and next generation peptide therapeutics for NASH (ALT-801) and
chronic hepatitis B (HepTcell™). For more information on Altimmune,
please visit www.altimmune.com.
Investor & Media Contacts:
| Will Brown |
Stacey Jurchison |
| Chief Financial Officer
|
Sr. Dir, Investor Relations |
| Phone: 240-654-1450 |
Phone : 410-474-8200 |
| wbrown@altimmune.com |
sjurchison@altimmune.com |
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Apr 2024 to May 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From May 2023 to May 2024
